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ON THE COMPARATIVE PROTHROMBIC ACTIVITY OF HUMAN
AND DOG BLOOD 1
By ARMAND J. QUICK AND CLARA V. HUSSEY
(From the Department of Biochemistry, Marquette University School of Medicine,

Milwaukee, Wis.)
(Submitted for publication April 14, 1951; accepted June 18, 1951)

Soon after the introduction of the one- and twostage methods for determining prothrombin, it was
noted that while the results obtained by the two
procedures generally agreed fairly well, marked
discrepancies occurred in certain specific instances.
Particularly puzzling has been the observation
that the prothrombic activity of human blood
as compared with dog blood, when measured by the
two tests, is markedly different. Warner, Brinkhous and Smith (1) reported that the prothrombin
concentration in dog blood is 350 units per cc. and
in human blood 295 units. More recently Murphy
and Seegers (2) found 190 to 205 units in dog and
290 to 315 in human blood. Mann and his associates (3, 4) reported that the average for dog
blood is 183 units per cc. and for human blood 319
units. These findings indicate that the prothrombin concentration as measured by the two-stage
method is approximately the same in the two species. When determined by the one-stage method,
the prothrombic activity of dog blood, in marked
contrast, is many-fold higher than in human blood
(5). The reason for this divergency has not been
satisfactorily explained, but obviously as long as
this problem remains unsolved, a marked gap in
the knowledge concerning prothrombin remains.
In the present investigation human and dog bloods
were studied by means of the prothrombin consumption test and by the adsorption and elution
technique for determining prothrombin with the
aim of obtaining new data that might be helpful in
arriving at a better understanding of what constitutes prothrombic activity.

platelet-poor plasma, blood is collected with a siliconecoated needle and syringe, and immediately transferred to
silicone-coated test tubes immersed in an ice bath. After
the tubes are chilled for 10 minutes, they are centrifuged
in an Angle Centrifuge at 8000 r.p.m. for 10 minutes.
One cc. of the plasma (having a platelet count less than
3000 per mm.) is transferred to a glass test tube and
placed in a water bath at 370 C. The fibrin is removed
as it forms by wrapping it about a glass stirring rod.
When the coagulation of fibrinogen is complete, the serum is tested every five minutes for its prothrombic activity. Usually it becomes constant in 15 minutes. The
prothrombin time is determined as follows: To a mixture
consisting of 0.1 cc. deprothrombinized oxalated rabbit
plasma, 0.1 cc. thromboplastin and 0.1 cc. 0.02 M CaCl2
solution, 0.1 cc. of serum is added by blowing from a
pipette. The formation of the clot is accurately timed.
The determination of prothrombin by the adsorption
and elution technique as developed by Stefanini and the
writer (8) was followed. In this test the prothrombin is
adsorbed with tricalcium phosphate and then eluted with
sodium citrate. Since one volume of eluate contains the
prothrombin of 10 volumes of plasma, the eluate is mixed
with nine volumes of deprothrombinized rabbit plasma for
assaying its prothrombic activity. Rabbit plasma has
been found to be a satisfactory assay medium because it
has a high and constant concentration of labile factor.
RESULTS

A comparative study of the prothrombic activity of human and dog plasmas and sera are recorded in Table I. The prothrombin time of normal human plasma is 12 seconds and of dog plasma
six seconds. The same values are obtained when
determined by the adsorption and elution procedure. On storing oxalated human and dog
plasma in an open container at 40 C., the prothrombin time steadily increases but in human
METHODS
plasma the rise is much more rapid. If deproThe prothrombin consumption time. The directions as thrombinized rabbit plasma, which is a rich source
previously outlined were followed (6, 7). In carrying of labile factor, is added to the stored human
out the prothrombin consumption test on serum from plasma, the prothrombin time is decreased to eight
seconds. Likewise, the eluate obtained from aged
1 This work was supported by a grant from the Division
of Research Grants and Fellowships of the National In- human plasma yields a prothrombin time of eight
seconds. When the labile factor is restored in
stitutes of Health, U. S. Public Health Service.
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TABLE I

The comparative prothrombic activity of dog and
human plasma and serum
Experi-

Proth rombin time
Directt Of eluate

ment

(sec.)

no.

1. Dog plasma fresh
6
2. Dog plasma fresh, 9 volumes +
Rabbit Ca3(PO4)2 plasma, 1 volume
6
3. Dog plasma stored 2 days
8
4. Dog plasma stored, 9 volumes +
Rabbit Ca3(PO4)2 plasma,* 1 volume 6
5. Dog serum from platelet-rich plasma 15
6. Dog serum from platelet-poor plasma 63
7. Normal human plasma fresh
12
8. Normal human plasma fresh,
9 volumes + Rabbit Ca3(PO4)2

(sec.)

6
6
6
15

61

12

plasma, 1 volume
121
9. Normal human plasma stored 2 days 17
10. Normal human plasma stored,
9 volumes + Rabbit Ca3(PO4)2
plasma, 1 volume
8
11. Normal human serum from
platelet-rich plasma
21
12. Normal human serum from
platelet-poor plasma
8
*
Fresh oxalated rabbit plasma treated with Ca3(PO4)2.

stored dog plasma, the prothrombin time again
becomes six seconds; likewise the eluate has this
value. There is, however, no increase in prothrombic activity during storage.
When platelet-rich human or dog plasma is
clotted, the serum has a comparatively marked decrease in prothrombic activity. If the plasma is
clotted after the removal of platelets, human serum has a prothrombin time of about eight seconds
while dog serum has a value of six and one-half
seconds. Native plasma, either platelet-rich or
poor, from a severe hemophiliac, when clotted in
glass yields a serum that has a prothrombin time of
eight to eight and one-half seconds. In every instance the direct prothrombin time agrees with that
obtained by the adsorption and elution procedure.
DISCUSSION

The simplest explanation for the difference of
the prothrombin times of dog and human plasmas
is that the former contains a much higher concentration of prothrombin than does human plasma.
This conclusion is supported by the finding that
on assaying the eluates of dog and human plasmas,
it is found that their prothrombin times are six
and 12 seconds respectively-the same as found
by the direct one-stage test.
Although it has been shown that increasing
the labile factor above the minimum level required

for optimum prothrombin time does not further
shorten it (9), it may still be claimed that the
higher concentration of labile factor in dog blood
might be responsible for the faster clotting time.
When the prothrombin is determined by the adsorption and elution procedure, the labile factor
is not a variable, because in the assay of the eluate,
a standard amount of deprothrombinized rabbit
plasma, which has a high concentration of labile
factor, is employed. The close agreement between
the results of the direct one-stage and the adsorption and elution method is good evidence that the
labile factor does not influence the results of the
one-stage method unless it is below the minimal
requirement.
When normal dog blood clots, the prothrombin
time of the serum increases because most of the
prothrombin is converted to thrombin. In the experiment recorded in Table I, Exp. 5, the prothrombin time of the serum is 15 seconds. By
means of the prothrombin curve for dog blood obtained by saline as a diluent (7), one can estimate
that over 90 per cent of the prothrombin in this
serum is consumed. In marked contrast, when
platelet-poor plasma clots, the prothrombin time
of the serum is practically the same as that of the
plasma (Table I, Exp. 6). On account of the
lack of platelets, so little thromboplastin apparently
becomes available that only a very small amount
of prothrombin is consumed. It is to be noted that
in serum from both platelet-rich and poor plasma
the prothrombin time by the direct one-stage
method agrees with the values obtained by the
adsorption and elution test. When oxalated dog
plasma is stored, the prothrombin time slowly increases, but the eluate from this aged plasma had
a prothrombin time of six to six and one-half seconds (Table I, Exp. 3) which clearly shows that
no significant change in prothrombin occurs in
dog plasma during short periods of storage.
When normal human blood clots, the serum has
a prothrombin time which usually ranges from 15
to 30 seconds. This illustrates that, as in dog
blood, much of the prothrombin is consumed during clotting. Fresh native plasma depleted of
platelets by high centrifugation when clotted in
glass yields a serum which has a prothrombin time
of about eight seconds (Table I, Exp. 12). Significantly, the serum obtained from the clotting of
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TABLE

II

The changes in prothrombic activity observed d in hemophilic
blood on storage and after clotti,ng
Experiment
no.

1. Hemophilic plasma fresh*
2. Hemophilic plasma stored 2 days
3. Hemophilic plasma stored,
9 volumes + Rabbit Ca3(PO4)2,
1 volume
4. Hemophilic serum from plateletrich plasma
5. Hemophilic serum from platelet*

poor plasma
From a severe hemophiliac.

time
)irect Of eluate

piIrothrombin

D

'sec.)
1[2
1[8
sec.)

(sec.)
(e.

12

8

8
8-9

8-9

8

8

plasma of a severe hemophilic subjectt likewise has
a prothrombin time of eight seconds even when the
platelets are not diminished (Table II Exps. 4 and
5). Furthermore, both normal an d hemophilic
blood when stored 24 to 48 hours hav ea prothrombin time of approximately eight secornds. Thus, a
marked and relatively fixed increase in prothrombic activity occurs in sera from platele t-free normal
plasma, from hemophilic blood or pl asmas and in
stored normal and hemophilic blood. In none of
these sera or plasmas is more than a very small
quantity of prothrombin consume d; therefore,
nearly all of the prothrombin remains;. This, however, does not account for the strikirig increase in
prothrombic activity. The most dirrect and simplest explanation is that an actual inccrease in prothrombin occurs. For this to haplpen one may
postulate that plasma contains an inactive or
precursor form of prothrombin.
Bordet (10)
developed the hypothesis that all prothrombin
(serozyme) in circulating blood is iin an inactive
form. Quick and Stefanini (9) cc)ncluded that
in human plasma part of the prothrornbin is active,
but a much greater proportion is in the precursor
state. This inactive prothrombin, lilke active prothrombin, is completely adsorbed andI eluted. The
eluate in contact with glass likewrise increases
markedly in prothrombic activity, prresumably because the precursor is gradually cbianged to active prothrombin. Recently it was found that the
quantity of thromboplastin requiredIfor maximum
prothrombic activity varies with the prothrombin
concentration (11). When the pr*othrombin is
reduced by means of Dicumarol or vritamin K deficiency, the thromboplastin requiremlent decreases.
Considerably more thromboplastin is needed to obtain the minimum prothrombin tiIme of stored

905

plasma than of fresh plasma, which suggests that
an increase of prothrombin itself occurs.
If the increase in prothrombic activity is not
due to an increase of active prothrombin, then
it becomes necessary to postulate that an accelerator is generated to account for the decrease of the
prothrombin time from the normal of 12 seconds to
eight seconds. Alexander and his associates (12)
have attempted to establish that such a specific
agent exists. They have named it spca (serum
prothrombin converting accelerator) because they
maintain that the prothrombic activity of serum
is due largely to the evolution of this factor during clotting. If their contentions are correct, then
the marked increase of prothrombic activity found
in the serum from hemophilic or from thrombocytopenic blood should be due to spca, but according to their findings this factor is low in these
sera (13, 14). From this it would follow that the
marked hyperprothrombic activity in these sera
is not due to the evolution of an accelerator but
to an actual increase in prothrombin.
According to Alexander, spca, like prothrombin,
is adsorbed by BaSO4 and eluted with sodium citrate. In isolating spca, they allow blood to clot
and treat the serum with BaSO4 (20 mgm. per 1 cc.
serum). From their statement (15): "most of the
prothrombic activity was in the supernatant" after
adsorption with BaSO4, one must infer that these
investigators assume that differential adsorption
occurs in which spca is separated from prothrombin. On repeating their procedure, it has been
found that as much as two-thirds of the prothrombic activity of serum is removed by 20 mgm. of
BaSO4 per 1 cc. (16). There is therefore a strong
probability that the separation of spca and prothrombin is more apparent than real and that the
product considered to be the accelerator contains
an undetermined amount of prothrombin. Alexander and Landwehr's (17) finding that the evolution of spca during storage is small in various hypoprothrombic states might well be explained by
a low concentration of prothrombin in the accelerator preparation. To determine how much of the
activity is due to prothrombin and how much to
an accelerator becomes not only a formidable but
a

speculative problem.
Thus, while the possibility of an accelerator

factor should not be ignored, it seems simpler and
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perhaps more firmly supported by experimental
evidence that the hyperprothrombic activity in the
conditions discussed is due to an actual increase
in active prothrombin. The statement of Stefanini
and Crosby (18) that the prothrombin time of serum is not influenced by the activation of the precursor of prothrombin in less than two hours after
the completion of clotting is not in accord with
the findings of the writers. In the clotting of native human plasma the prothrombin time of the
serum attains a constant value in about 15 minutes
after all the fibrinogen has been converted to fibrin.
In oxalated plasma, the conversion of inactive
prothrombin to the active state is slow. At 40 C.
the reaction usually requires more than 24 hours
to go to completion, even in contact with a glass
surface, and in a silicone-coated container it even
takes considerably longer. This permits the removal of both prothrombin and prothrombinogen
from oxalated plasma by adsorption with tricalcium phosphate, and the subsequent recovery of
both forms by elution with sodium citrate.
The finding that neither storage nor the clotting
of platelet-poor dog plasma causes an increase of
prothrombic activity such as is observed in human
plasma, makes it unlikely that dog blood contains
a prothrombin converting factor of the type of
spca. One is at a loss, therefore, to find a better
explanation for the high prothrombic activity of
dog blood than that it contains a much higher concentration of active prothrombin than does human
blood, but has little or no inactive prothrombin.

Human plasma on storage likewise shows a progressive decrease of prothrombic activity but when
the labile factor is restored, the prothrombin time
becomes shorter than that of the fresh plasma. A
similar increase in prothrombic activity is found
when normal platelet-poor plasma, or hemophilic
plasma clots.
Possible explanations for these findings are
discussed. It is concluded that dog blood contains a high concentrate of free or active prothrombin but little or no inactive prothrombin, whereas
human plasma has a much smaller amount of
free prothrombin, but a high concentration of inactive prothrombin (prothrombinogen), which in
contact with a glass surface becomes converted to
the active state.
1.

2.

3.
4.

5.
6.

SUM MARY

The comparative prothrombic activity of dog
and human blood were studied by means of the
one-stage prothrombin test, the prothrombin consumption test and the adsorption and elution technique for determining prothrombin.
It was found that the prothrombic activity of
dog blood is much greater than that of human
blood. When oxalated dog plasma is stored, the
prothrombin time is increased due to loss of labile
factor. When the latter is restored, the prothrombin time returns to the value obtained for fresh
plasma. The serum from platelet-poor normal
plasma has a prothrombin time only slightly less
than that of plasma.

7.
8.

9.
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